# US 2023/0265107 A1 · Pb2 inhibitor, and preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265107 A1
- Document ID: US20230265107A1
- Status: Published application
- Kind: A1
- Application number: 18/015,309
- Filed: 2021-07-09
- Published: 2023-08-24
- Earliest claimed: 2020-07-10
- Assignees: Sichuan Haisco Pharmaceutical Co., Ltd.
- Applicants: Sichuan Haisco Pharmaceutical Co., Ltd.
- Inventors: Yao LI; Lei CHEN; Zongjun SHI; Guobiao ZHANG; Wenjing WANG; Fei YE; Gang HU; Tiancheng HE; Haodong WANG; Jia NI; Chen ZHANG; Pangke YAN
- Web page: https://patentgrep.com/patent/US20230265107A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P 31/16: for influenza or rhinoviruses
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of formula (I); a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt, a co-crystal or a prodrug thereof, or a pharmaceutical composition containing same; and the use thereof as a PB2 inhibitor in the preparation of a drug for treating related diseases. Each group in formula (I) is as defined in the description. Cy1-L1-Cy2-L2-Cy3 (I)

## Claims

### Claim 1

A compound of formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt, a co-crystal or a prodrug thereof,
Cy1-L1-Cy2-L2-Cy3 (I)
wherein Cy1 is selected from
Y1 is selected from —CH— or —N—;
n is selected from 1, 2 or 3;
R1 and R2 are each independently selected from F, Cl, Br, NH2, C1-6 alkyl or C3-6 monocyclic cycloalkyl, and the R1 and R2 are optionally further substituted with 1-5 groups selected from halogen, OH or deuterium;
Cy2 is selected from a bond, C3-12 carbocycle or 3-12-membered heterocycle, and the Cy2 is optionally further substituted with 1-5 groups selected from RA;
each RA is independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 5-12-membered heteroaryl, phenyl, —NRBC(O)C1-6 alkyl, —C(O)NRBC1-6 alkyl, —C(O)C1-6 alkyl, CN, ═O, C1-6 alkoxy C(O)—, —COOH, OH, —NRBRC, deuterium, —SH, —S(C1-6 alkyl), —S(O)2(C1-6 alkyl) or C3-6 monocyclic cycloalkyl, and the RA is optionally further substituted with 1-5 groups selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, halo C1-6 alkyl, halo C1-6 alkoxy, —Si(C1-6 alkyl)3, OH, 5-6-membered heteroaryl, C3-6 monocyclic cycloalkyl, —S(C1-6 alkyl) or deuterium;
Cy3 is selected from
and the Cy3 is optionally substituted with 1-5 groups selected from Rcy3;
t is selected from 0, 1, 2, 3 or 4;
each Y2 is independently selected from —CH2—, —N—, —NH—, O, S, S(O) and S(O)2, and each H atom in the Y2 can be independently substituted with Rcy3 group;
each Rcy3 is independently selected from F, Cl, Br, OH, CN, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl and hydroxy C1-6 alkyl;
each R3 is independently selected from H and C1-6 alkyl;
L1 is selected from a bond, C2-6 alkynylene, C2-6 alkenylene or —C(O)—;
L2 is selected from a bond, —NRB— or —C(O)NRB—;
and RB and RC are each independently selected from H, deuterium, C1-6 alkyl, halo C1-6 alkyl, —OC(O)CH3 or deuterated C1-6 alkyl.

### Claim 2 (depends on 1)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 1, having a structure of formula (II), (III), (IV) or (V):
Cy1—Cy2a—NH—Cy3 (II)
Cy1—Cy2b—Cy3 (III)
Cy1-L1a-Cy2c-L2a-Cy3 (IV)
Cy1-L1b-L2b-Cy3 (V)
wherein
Cy1 is selected from
Cy3 is selected from
and the Cy3 is optionally substituted with 1-5 groups selected from Rcy3;
each Y2 is independently selected from —CH2—, —N—, —NH—, O, S, S(O) and S(O)2, and each H atom in the Y2 can be independently substituted with Rcy3 group;
t is selected from 1, 2, 3 or 4;
each Rcy3 is independently selected from F, Cl, Br, OH, CN, C1-4 alkyl, C1-4 alkoxy, halo C1-4 alkyl or hydroxy C1-4 alkyl;
Cy2a is selected from the following groups, wherein * represents the coupling site of Cy2a with NH:
(e) 5-membered heteroaryl, 5-membered unsaturated monocyclic heterocycloalkyl and 6-membered saturated monocyclic heterocycloalkyl;
(f) 6-membered unsaturated monocyclic heterocycloalkyl;
wherein the groups of (a)-(f) in Cy2a are optionally further substituted with 1-5 groups selected from RA, and the group of (g) in Cy2a is substituted with 1 group selected from RD;
when Cy1 is selected from
the group of (h) in Cy2a is substituted with 1-3 groups selected from RE; or
when Cy1 is selected from
and Cy2a is (h), Cy3 is substituted with 1-5 groups selected from Rcy3; or
when Cy1 is selected from
and Cy2a is (h), Cy3 is selected from
and t 2, 3 or 4;
when Cy1 is selected from
the group of (h) in Cy2a is optionally further substituted with 1-3 groups selected from RA;
each ring A is independently selected from 4-6-membered monocyclic cycloalkyl, 4-6-membered monocyclic heterocycloalkyl, 5-6-membered heteroaryl or phenyl;
each ring C is independently selected from 5-membered monocyclic cycloalkyl, 5-membered monocyclic heterocycloalkyl or 5-membered heteroaryl;
each ring E is independently selected from 6-membered monocyclic cycloalkyl, 6-membered monocyclic heterocycloalkyl, 6-membered heteroaryl or phenyl;
X11, X12 and X13 are each independently selected from —CH—, —CRA—, —CH2—, —CHRA—, —C(RA)2—, —N—, —NH—, —NRA—, O, S, S(O) or S(O)2, X14 and X15 are each independently selected from —C—, —CH—, —CRA— or —N—, and ring B is a saturated ring, a partially unsaturated ring or a heteroaryl ring;
X21, X22, X23 and X24 are each independently selected from —CH—, —CRA—, —CH2—, —CHRA—, —C(RA)2—, —N—, —NH—, —NRA—, O, S, S(O) or S(O)2, X25 and X26 are each independently selected from —C—, —CH—, —CRA— or —N—, and ring D is a saturated ring, a partially unsaturated ring, a benzene ring or a heteroaryl ring, provided that D-fused ring C does not form substituted or unsubstituted
X31, X32, X33 and X34 are each independently selected from —CH—, —CRA—, —CH2—, —CHRA—, —C(RA)2—, —N—, —NH—, —NRA—, O, S, S(O) or S(O)2, X35 and X36 are each independently selected from —C—, —CH—, —CRA— or —N—, and ring F is a saturated ring, a partially unsaturated ring, a benzene ring or a heteroaryl ring, provided that F-fused ring E does not form substituted or unsubstituted
each RA is independently selected from halogen, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, 5-12-membered heteroaryl, phenyl, —NRBC(O)C1-6 alkyl, —C(O)NRBC1-6 alkyl, —C(O)C1-6 alkyl, CN, ═O, C1-6 alkoxy C(O)—, —COOH, OH, —NRBRC, deuterium, —SH, —S(C1-6 alkyl), —S(O)2(C1-6 alkyl) and C3-6 monocyclic cycloalkyl, and the RA is optionally further substituted with 1-5 groups selected from halogen, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halo C1-6 alkoxy, —Si(C1-6 alkyl)3, OH, 5-6-membered heteroaryl, C3-6 monocyclic cycloalkyl, —S(C1-6 alkyl) and deuterium;
each RD is selected from C1-6 alkyl, 5-6-membered heteroaryl and phenyl, and the heteroaryl and phenyl are substituted with 1-2 groups selected from —Si(C1-6 alkyl)3;
each RE is selected from hydroxy C1-6 alkyl, halo C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 5-12-membered heteroaryl, phenyl, —NRBC(O)C1-6 alkyl, —C(O)NRBC1-6 alkyl, —C(O)C1-6 alkyl, ═O, C1-6 alkoxy C(O)—, —COOH, OH, —NRBRC, deuterium, —SH, —S(C1-6 alkyl), —S(O)2(C1-6 alkyl), C3-6 monocyclic cycloalkyl and C3-6 monocyclic heterocyclic cycloalkyl, and the RE is optionally further substituted with 1-5 groups selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, halo C1-6 alkyl, halo C1-6 alkoxy, —Si(C1-6 alkyl)3, OH, 5-6-membered heteroaryl, C3-6 monocyclic cycloalkyl, —S(C1-6 alkyl) and deuterium;
Cy2b is selected from
wherein * represents the coupling site of Cy2b with
and the Cy2b is optionally substituted with 1-5 groups selected from RA;
Cy2c is selected from C3-12 carbocycle and 5-12-membered heterocycle, and the Cy2c is optionally further substituted with 1-5 groups selected from RA;
L1a is selected from a bond, C2-4 alkynylene, C2-4 alkenylene or —C(O)—; L2a is selected from —NRB— and -*C(O)NRB—, wherein * represents the coupling site of L2a with Cy2c, provided that when L1a is selected from a bond, L2a is selected from -*C(O)NRB—;
L1b is selected from C2-4 alkynylene or C2-4 alkenylene, and L2b is selected from —NRB— or -*C(O)NRB—, wherein * represents the coupling site of L2b with L1b;
RB and RC are each independently selected from H, deuterium, C1-6 alkyl, —OC(O)CH3, halo C1-6 alkyl and deuterated C1-6 alkyl;
provided that Cy2a is not selected from substituted or unsubstituted
and substituted or unsubstituted

### Claim 3 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy1 is selected from
or
Cy1 is selected from
or
Cy1 is selected from

### Claim 4 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy3 is selected from
and the Cy3 is optionally substituted with 1-3 groups selected from Rcy3; or
Cy3 is selected from
and the Cy3 is optionally substituted with 1-3 groups selected from Rcy3, wherein t is selected from 1, 2 or 3, each Y2 is independently selected from —CH2—, —NH—, O and S, and each H atom in the Y2 can be independently substituted with Rcy3 group; or
Cy3 is selected from
and the Cy3 is optionally substituted with 1-3 groups selected from Rcy3.

### Claim 5 (depends on 4)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 4, wherein
Cy3 is selected from

### Claim 6 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
each Rcy3 is independently selected from F, Cl and CN.

### Claim 7 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy3 is selected from
and the Cy3 is optionally substituted with 1-3 groups selected from Rcy3;
and Cy1 is selected from

### Claim 8 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy2a is selected from
and the Cy2a is optionally substituted with 1-3 groups selected from RA; or
Cy2a is selected from
and is substituted with 1 group selected from methyl or 5-membered heteroaryl, and the 5-membered heteroaryl is substituted with 1 trimethylsilyl group; or
Cy1 is selected from
Cy2a is selected from
and is substituted with 1 group selected from hydroxy C1-6 alkyl, halo C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 5-6-membered heteroaryl, —NRBC(O)C1-6 alkyl, —C(O)NRBC1-6 alkyl, —C(O)C1-6 alkyl, C1-6 alkoxy C(O)—, —COOH, OH, —NRBRC, deuterium, C3-6 monocyclic cycloalkyl or C3-6 monocyclic heterocyclic cycloalkyl, and the heteroaryl is optionally further substituted with 1-3 groups selected from halogen, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halo C1-6 alkoxy, —Si(C1-3 alkyl)3, OH, 5-6-membered heteroaryl, C3-6 monocyclic cycloalkyl, —S(C1-6 alkyl) and deuterium; or
Cy1 is selected from
Cy2a is selected from
and is optionally substituted with 1-2 groups selected from hydroxy C1-6 alkyl, halo C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 5-6-membered heteroaryl, —NRBC(O)C1-6 alkyl, —C(O)NRBC1-6 alkyl, —C(O)C1-6 alkyl, C1-6 alkoxy C(O)—, —COOH, OH, —NRBRC, deuterium, C3-6 monocyclic cycloalkyl and C3-6 monocyclic heterocyclic cycloalkyl, and the heteroaryl is optionally further substituted with 1-3 groups selected from halogen, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halo C1-6 alkoxy, —Si(C1-3 alkyl)3, OH, 5-6-membered heteroaryl, C3-6 monocyclic cycloalkyl, —S(C1-6 alkyl) and deuterium.

### Claim 9 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy1 is selected from
Cy2a is selected from a five-membered ring fused five-membered ring, a five-membered ring fused six-membered ring, a six-membered ring fused five-membered ring and a six-membered ring fused six-membered ring, and the Cy2a is optionally further substituted with 1-5 groups selected from RA; or
Cy2a is selected from a five-membered heteroaryl fused six-membered heteroaryl, a six-membered heteroaryl fused six-membered heteroaryl, a five-membered heteroaryl fused five-membered heteroaryl and a six-membered heteroaryl fused five-membered heteroaryl, the Cy2a is optionally further substituted with 1-3 groups selected from halogen, hydroxy C1-6 alkyl, halo C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 5-6-membered heteroaryl, —NRBC(O)C1-6 alkyl, —C(O)NRBC1-6 alkyl, —C(O)C1-6 alkyl, C1-6 alkoxy C(O)—, —COOH, OH, —NRBRC, deuterium, C3-6 monocyclic cycloalkyl and C3-6 monocyclic heterocyclic cycloalkyl, and the heteroaryl is optionally further substituted with 1-3 groups selected from halogen, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halo C1-6 alkoxy, —Si(C1-3 alkyl)3, OH, 5-6-membered heteroaryl, C3-6 monocyclic cycloalkyl, —S(C1-6 alkyl) and deuterium; or
Cy2a is selected from a five-membered heteroaryl fused six-membered heteroaryl, a six-membered heteroaryl fused six-membered heteroaryl, a five-membered heteroaryl fused five-membered heteroaryl and a six-membered heteroaryl fused five-membered heteroaryl, and the Cy2a is optionally further substituted with 1-3 groups selected from halogen and —NRBRC; or
Cy2a is selected from
and the Cy2a is optionally further substituted with 1-3 groups selected from halogen and —NRBRC; or
Cy2a is selected from

### Claim 10 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy1 is selected from
and Cy2a is selected from

### Claim 11 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy1 is selected from
and Cy2a is selected from

### Claim 12 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy2b is selected from
wherein * represents the coupling site of Cy2b with

### Claim 13 (depends on 2)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 2, wherein
Cy2c is selected from 5-membered heteroaryl, 6-membered heteroaryl or C3-6 cycloalkyl, and the Cy2c is optionally further substituted with 1-5 groups selected from RA; or
Cy2c is selected from
and the Cy2c is optionally substituted with 1-3 groups selected from RA; or
Cy2c is selected from

### Claim 14 (depends on 1)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 1, wherein
each RA is independently selected from halogen, C1-4 alkyl, 5-6-membered heteroaryl, phenyl, —NRBC(O)C1-4 alkyl, —C(O)NRBC1-4 alkyl, —C(O)C1-4 alkyl, CN, ═O, —C(O)C1-4 alkoxy, C2-6 alkenyl, C2-6 alkynyl, —COOH, OH, —NRBRC, deuterium, —SH, —S(C1-4 alkyl), —S(O)2(C1-4 alkyl) and C3-6 monocyclic cycloalkyl, and the RA is optionally further substituted with 1-3 groups selected from halogen, C1-4 alkyl, C1-4 alkoxy, halo C1-4 alkyl, halo C1-4 alkoxy, C1-6 alkylamino, —Si(C1-4 alkyl)3, OH, 5-6-membered heteroaryl, C3-6 monocyclic cycloalkyl, —S(C1-4 alkyl) and deuterium; or
each RA is independently selected from halogen, C1-4 alkyl, 5-6-membered heteroaryl, phenyl, —NRBC(O)C1-4 alkyl, —C(O)NRBC1-4 alkyl, —C(O)C1-4 alkyl, CN, ═O and amino, and the RA is optionally further substituted with 1-3 groups selected from halogen, C1-2 alkyl and —Si(C1-2 alkyl)3.

### Claim 15 (depends on 1)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 1, wherein
RB and RC are each independently selected from H, deuterium, —OC(O)CH3 or C1-3 alkyl.

### Claim 16 (depends on 1)

The compound of formula (I), or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 1, wherein the compound is selected from one of the following structures:

### Claim 17 (depends on 1)

A pharmaceutical composition, wherein the pharmaceutical composition contains the compound, or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 1, and a pharmaceutically acceptable carrier and/or excipient.

### Claim 18 (depends on 1)

Use of the compound, or the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the metabolite, the pharmaceutically acceptable salt, the co-crystal or the prodrug thereof according to claim 1, in the preparation of a drug for treating a PB2-mediated disease.

### Claim 19 (depends on 18)

The use according to claim 18, wherein the PB2-mediated disease is a tumor or an autoimmune disease.
